


Accepted Manuscript

Choroidal Changes after Suprachoroidal Injection of Triamcinolone in Eyes with Macular Edema Secondary to Retinal Vein Occlusion

Alex S. Willoughby, Vivian S. Vuong, David Cunefare, Sina Farsiu, Glenn Noronha, Ronald P. Danis, Glenn Yiu



PII: S0002-9394(17)30514-7

DOI: [10.1016/j.ajo.2017.11.020](https://doi.org/10.1016/j.ajo.2017.11.020)

Reference: AJOPHT 10339

To appear in: *American Journal of Ophthalmology*

Received Date: 3 August 2017

Revised Date: 21 November 2017

Accepted Date: 25 November 2017

Please cite this article as: Willoughby AS, Vuong VS, Cunefare D, Farsiu S, Noronha G, Danis RP, Yiu G, Choroidal Changes after Suprachoroidal Injection of Triamcinolone in Eyes with Macular Edema Secondary to Retinal Vein Occlusion, *American Journal of Ophthalmology* (2017), doi: 10.1016/j.ajo.2017.11.020.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Purpose: To evaluate choroidal and suprachoroidal changes following suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).

Design: Prospective cohort study within a randomized, controlled phase 2 clinical trial.

Methods: Enhanced-depth imaging optical coherence tomography (EDI-OCT) images were analyzed from 38 eyes of 38 treatment naïve patients with macular edema due to RVO, enrolled in the prospective Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received either a suprachoroidal injection of CLS-TA with an intravitreal injection of aflibercept (combination arm) or only an intravitreal injection of aflibercept (monotherapy arm) followed by monthly intravitreal aflibercept injections in both arms based on pro re nata (PRN) criteria.

Results: Macular choroidal thickness measured to the outer choroidal vessel lumen (vascular choroidal thickness, VCT), outer choroid stroma (stromal choroidal thickness, SCT), or inner scleral border (total choroidal thickness, TCT) showed no significant changes over 3 months in both study arms ($P = 0.231-0.342$). Eyes that received combination therapy showed a trend toward thickening of the suprachoroidal space (SCS) compared with monotherapy alone ($13.4 \mu\text{m}$ vs $5.3 \mu\text{m}$ at 3 months; $P=0.077$). In the 15 eyes that demonstrated a visible SCS at baseline, the SCS expanded significantly after suprachoroidal CLS-TA injection ($16.2 \mu\text{m}$ to $27.8 \mu\text{m}$ at 3 months; $P=0.033$).

Conclusions: Suprachoroidal injection of CLS-TA does not alter choroidal thickness in eyes with macular edema due to RVO, but may result in expansion of the SCS.

Download English Version:

<https://daneshyari.com/en/article/8790726>

Download Persian Version:

<https://daneshyari.com/article/8790726>

[Daneshyari.com](https://daneshyari.com)